Vasoproliferation and antiproliferative treatment options in pulmonary arterial hypertension

Recent Patents on Cardiovascular Drug Discovery

Volumn 4, Issue 2, 2009, Pages 142-149

  Blaukovitsch, Markus ^a   Zabel, Peter ^a   Hauber, Hans Peter ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Endothelin; Inflammation; Inhibitor; Kinase; Proliferation; Prostanoid; Pulmonary hypertension; Rho and serotonin

Indexed keywords

ADRENOMEDULLIN; ENDOTHELIN RECEPTOR ANTAGONIST; GUANYLATE CYCLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SEROTONIN; SILDENAFIL; SIMVASTATIN; SORAFENIB; ANTIINFLAMMATORY AGENT; CARDIOVASCULAR AGENT; ENZYME INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; GENE FUNCTION; HUMAN; PATENT; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VASODILATATION; ANIMAL; CELL PROLIFERATION; DRUG EFFECT; ENDOTHELIUM CELL; IMMUNOLOGY; INFLAMMATION; PATHOLOGY; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE;

EID: 70149104935     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489009788452968     Document Type: Review

References (97)

1. Deng Z, Morse HJ, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744.
2. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001; 344: 1031-1037.
3. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
4. Perros F, Montani D, Dorfmüller P, et al. Platelet-derived growth factor expression and function in patients with idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-88.
5. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
6. Yu Y, Sweeny M, Zhang S, et al. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am J Physiol Cell Physiol 2003; 284: C316-C330.
7. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-1316.
8. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11: 554-559.
9. Rosenkranz S, Kazlaukas A. Evidence for distinct signalling properties and biological responses induced by PDGF receptor α and β subtypes. Growth Factors 1999; 16:201-216.
10. Ten Freyhaus H, Kappert K, Dagnell M, Leuchs M, Vantler M, Rosenkranz S. Hypoxia enhances PDGF signalling in the pulmonary vasculature by downregulation of protein tyrosine phosphatases (PTPs) Abstract. 4th World Symposium on Pulmonary Hypertension. Dana Point: CA 2008.
11. McMurty IF, Bauer NR, Fagan KA, Nagaoka T, Gebb SA, Oka M. Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension. Adv Exp Med Biol 2003; 543: 127-137.
12. Ishizaki T, Maekawa M, Fujikawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996; 15: 1885-1893.
13. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996; 15: 2208-2216.
14. Kureishi Y, Kobayashi Y, Amano M, et al. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem 1997; 272: 12257-12260.
15. Wang Z, Jin N, Ganguli S, Schwartz DR, Li L, Rhoades RA. Rhokinase activation is involved in hypoxia-induced pulmonary vasoconstriction. Am J Respir Cell Mol Biol 2001; 25: 628-635.
16. Wang Z, Lanner MC, Jin N, Schwrtz D, Li L, Rhoades RA. Hypoxia inhibits myosin phosphatase in pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2003; 29: 465-471.
17. Oka M, Fagan KA, Jones PL, McMurtry IF. Therapeutic potential of RhoA/ Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008; 155: 444-454.
18. Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2007; 49: 85-89.
19. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rhokinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70: 174-178.
20. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615-675.
21. Vanhaesebroeck B, Leevers SJ, Ahmadi K, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001; 70: 535-602.
22. Goncharova EA, Ammit AJ, Irani C, et al. PI3K is required for proliferation and migration of pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002; 283: L354-L363.
23. Egushi S, Iwasaki H, Ueno H, et al. Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser411 in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. J Biol Chem 1999; 274: 36843-36851.
24. Teng X, Li D, Champion HC, Johns RA. FIZZ1/RELMα, a novel hypoxia-induced mitogenic factor in lung with vasoconstrictive and angiogenic properties. Circ Res 2003; 92: 1065-1067.
25. Capraro, H.G., Furet, P., Imbach, P., Stauffer, F.: WO2008052733A1 (2008).
26. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.
27. Eddahibi S, Raffestin B, Pham I, et al. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol 1997; 272: H1173-H1181.
28. Eddahibi S, Fabre V, Boni C, et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cell. Relationship with the mitogenic action of serotonin. Circ Res 1999; 84: 329-336.
29. Marcos E, Adnot S, Pham MH, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003; 168: 487-493.
30. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005; 111: 2812-2819.
31. Kozhevnikova VV, Medvedeva NA. Chronic administration of serotonin transporter inhibitor (fluoxetine) decreases monocrotaline-induced pulmonary hypertension in rats. Eksp Klin Farmakol 2007; 70: 15-18.
32. Hoeper MM, Ghofrani HA, Grimminger F, Rosenkrankz S. Dana Point: What is new in the treatment of pulmonary hypertension? Dtsch Med Wochenschr 2008; 133: S191-S195.
33. Mittal M, Roth M, Konig P, et al. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 2007; 101: 258-267.
34. Nisbet RE, Graves AS, Kleinhenz DJ, et al. The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice. Am J Respir Cell Mol Biol 2008. Epub ahead of print.
35. Schermuly RT, Stasch JP, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32: 881-891.
36. Dumitrascu R, Weissmann N, Ghofrani HA, et al. Activation of the soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodelling. Circulation 2006; 113: 286-295.
37. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension. N Engl J Med 2004; 351: 1425-1436.
38. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
39. Essayan DM, Huang SK, Undem BJ, Kagey-Sobotka A, Lichtenstein LM. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 1994; 153: 3408-3416.
40. Bloom TJ, Beavo JA. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci USA 1996; 93: 14188-14192.
41. Schermuly RT, Pullamsetti SS, Kwapiszewska G, et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodelling therapy. Circulation 2007; 115: 2331-2339.
42. Beltowski J, Jamroz A. Adrenomedullin - What do we know 10 years since its discovery? Pol J Pharmacol 2004; 56: 5-27.
43. Jougasaki M, Burnett JC Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci 2000; 66: 855-872.
44. Kakishita M, Nishikimi T, Okano Y, et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond) 1999; 96: 33-39.
45. Yoshihara F, Nishikimi T, Horio T, et al. Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline. Eur J Pharmacol 1998; 355: 33-39.
46. Nagaya N, Nishikimi T, Uematsu M, et al. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart 2000; 84: 653-658.
47. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1723-1739.
48. Rubin LJ, Roux S. Bosentan: A dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002; 11: 991-1002.
49. Clozel M, Gray GA. Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 1995; 26 (Suppl 3): S262-S264.
50. Iqbal J, Sanghia R, Das SK. Endothelin receptor antagonists: An overview of their synthesis and structure-activity relationship. Mini Rev Med Chem 2005; 5: 381-408.
51. Channick RN, Simonneau G, Sitbon O, et al. Effects of a dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
52. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
53. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447.
54. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-2056.
55. Jürgens UR, Racke K, Uen S, et al. Inflammatory responses after endothelin B (ETB) receptor activation in human monocytes: New evidence for beneficial anti-inflammatory protency of ETB-receptor antagonism. Pulm Pharmacol Ther 2008; 21: 533-539.
56. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
57. Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: 1139-1141.
58. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 39-45.
59. Itoh T, Nagaya N, Fujii T, et al. Combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 34-38.
60. Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2004; 99: 1-8.
61. Wharton J, Strange JW, Møller GMO, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172: 105-113.
62. Li B, Yang L, Shen J, Wang C, Jiang Z. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phophatase-1 and degradation of extracellular signal-regulated 1/2 phosphporylation. Anesth Analg 2007; 105: 1034-1041.
63. Jacob A, Molkentin JD, Smolenski A, Lohmann SM, Begum N. Insulin inhibits PDGF-directed VSMC migration via NO/cGMP increase of MKP-1 and its inactivation of MAPKs. Am J Physiol Cell Physiol 2002; 283: C704-C713.
64. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
65. Cohen MH, Johnson JR, Pazdur R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-942.
66. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002; 8: 3034-3038.
67. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413.
68. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61: 736.
69. Hernández GFJ, Palma CMJ, Leon GR, Rasco GR, Medina OC, Román SJ. Experience with imatinib to treat pulmonary arterial hypertension. Arch Bronconeumol 2008; 44: 689-691.
70. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalling. Mol Cancer Ther 2008; 7: 3129-3140.
71. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 2008; 33: 278-291.
72. Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodelling. Circulation 2008; 118: 2081-2090.
73. Kip1. J Biol Chem 1999; 274: 21926-21931.
74. Indolfi C, Cioppa A, Stabile E, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000; 35: 214-221.
75. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425- 430.
76. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997; 11: 2295-2322.
77. Laufs U, La Fata V, Liao JK. Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725-31729.
78. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-1235.
79. Guerard P, Rakotoniaina Z, Goirand F, et al. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 401-414.
80. Rakotoniaina Z, Guerard P, Lirussi F, et al. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: Comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch Pharmacol 2006; 374: 195-206.
81. Satoh K, Ichihara K, Landon EJ, Inagami T, Tang H. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors block calcium-dependent tyrosine kinase Pyk2 activation by angiotensin II in vascular endothelial cells: Involvement of geranylgeranylation of small G protein Rap1. J Biol Chem 2001; 276: 15761-15767.
82. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002; 116: 1403-1408.
83. Fouty BW, Rodman DM. Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway. Circ Res 2003; 92: 501-509.
84. Girgis RE, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1105-L1110.
85. Barreto AC, Maeda NY, Soares RP, Cicero C, Lopes AA. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: A placebo-controlled study. Braz J Med Biol Res 2008; 41: 657-663.
86. Boettcher, A., Buschmann, N., Furet, P., Groell, J.-M., Kallen, J., Hergovich, L.J, Masuya, K., Mayr, L., Vaupel, A.: WO2008119741A2 (2008).
87. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7: 979-987
88. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function. A novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009; 49: 223-241.
89. Tao Q, Zhang Z, Xu Y. Apoptosis versus proliferation activities and relative mechanism in chronic obstructive pulmonary disease. Zhonghua Yi Xue Za Zhi 1998; 78: 574-577.
90. Mastalerz, H., Wittman, M.D., Zimmermann, K., Saulnier, M.G., Velaparthi, U., Vyas, D.M., Zhang, G., Johnson, W.L., Frennesson, D.B., Sang, X., Liu, P., Langley, D.R.: WO2008005956A2 (2008).
91. Wrobleski ST, Lin S, Hynes J Jr, et al. Synthesis and SAR of new pyrrolo2,1-f1,2,4triazines as potent p38 alpha MAP kinase inhibitors. Bioorg Med Chem Lett 2008; 18: 2739-2744.
92. Borzilleri RM, Cai ZW, Ellis C, et al. Synthesis and SAR of 4-(3-hydroxphenylamino)pyrrolo2,1-f1,2,4triazine based VEGFR-2 kinase inhibitors. Bioorg Med Chem Lett 2005; 15: 1429-1433.
93. Mastalerz H, Chang M, Chen P, et al. New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinase. Bioorg Med Chem Lett 2007; 17: 2036-42.
94. Gavai, A.V., Chen, P., Zhao, Y.: US20087358256 (2008).
95. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000; 6: 698-702.
96. Merklinger SL, Jones PL, Mertinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005; 112: 423-431.
97. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.